Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Français
Author : 
Butts, C ; Socinski, MA ; Mitchell, PL ; Thatcher, N ; Havel, L ; Krzakowski, M & al
Newspaper edition : 
Lancet Oncol. - Année 2014 - Volume 15 - Page 56-68 - PMID 24331154